Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Peripheral Arterial Disease | 18 | 2023 | 1169 | 3.160 |
Why?
|
Intermittent Claudication | 6 | 2023 | 309 | 2.760 |
Why?
|
Stents | 22 | 2021 | 3257 | 1.970 |
Why?
|
Angioplasty, Balloon, Coronary | 14 | 2020 | 1874 | 1.580 |
Why?
|
Lower Extremity | 11 | 2023 | 1145 | 1.540 |
Why?
|
Drug-Eluting Stents | 6 | 2023 | 753 | 1.470 |
Why?
|
Femoral Artery | 7 | 2023 | 841 | 1.420 |
Why?
|
Coronary Artery Disease | 29 | 2021 | 6416 | 1.410 |
Why?
|
Ticlopidine | 5 | 2016 | 899 | 1.400 |
Why?
|
Ischemia | 8 | 2023 | 1908 | 1.380 |
Why?
|
Heptanoic Acids | 9 | 2009 | 343 | 1.350 |
Why?
|
Platelet Aggregation Inhibitors | 9 | 2023 | 3066 | 1.280 |
Why?
|
Acute Coronary Syndrome | 7 | 2023 | 2331 | 1.240 |
Why?
|
Endovascular Procedures | 6 | 2023 | 1947 | 1.230 |
Why?
|
Ultrasonography, Interventional | 12 | 2019 | 1480 | 1.060 |
Why?
|
Endothelium, Vascular | 30 | 2014 | 4454 | 1.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2012 | 3233 | 1.050 |
Why?
|
Coronary Disease | 20 | 2008 | 6068 | 1.050 |
Why?
|
Pyrroles | 9 | 2009 | 1142 | 0.980 |
Why?
|
Leg | 3 | 2016 | 1107 | 0.980 |
Why?
|
Angioplasty, Balloon | 7 | 2020 | 654 | 0.970 |
Why?
|
Angioplasty | 4 | 2020 | 363 | 0.900 |
Why?
|
Cardiology | 7 | 2016 | 1654 | 0.900 |
Why?
|
Angina Pectoris | 6 | 2009 | 976 | 0.860 |
Why?
|
Myocardial Infarction | 23 | 2023 | 11668 | 0.780 |
Why?
|
C-Reactive Protein | 9 | 2013 | 3752 | 0.770 |
Why?
|
Vasodilation | 10 | 2019 | 947 | 0.740 |
Why?
|
Anticholesteremic Agents | 9 | 2009 | 979 | 0.700 |
Why?
|
Angina, Unstable | 5 | 2004 | 926 | 0.690 |
Why?
|
Metals | 3 | 2015 | 718 | 0.680 |
Why?
|
Arteriosclerosis | 14 | 2004 | 1092 | 0.670 |
Why?
|
Vascular Patency | 6 | 2023 | 888 | 0.660 |
Why?
|
Persian Gulf Syndrome | 1 | 2019 | 45 | 0.660 |
Why?
|
Vascular Resistance | 4 | 2019 | 943 | 0.660 |
Why?
|
Veterans | 2 | 2023 | 2505 | 0.640 |
Why?
|
Coronary Vasospasm | 2 | 2014 | 88 | 0.640 |
Why?
|
Coronary Artery Bypass | 6 | 2020 | 2272 | 0.630 |
Why?
|
Coronary Stenosis | 4 | 2018 | 836 | 0.620 |
Why?
|
Popliteal Artery | 3 | 2023 | 314 | 0.580 |
Why?
|
Withholding Treatment | 1 | 2021 | 596 | 0.570 |
Why?
|
Coronary Vessels | 13 | 2014 | 3097 | 0.570 |
Why?
|
Coronary Angiography | 16 | 2014 | 4560 | 0.550 |
Why?
|
Arterial Occlusive Diseases | 2 | 2011 | 792 | 0.540 |
Why?
|
United States Department of Veterans Affairs | 3 | 2016 | 873 | 0.510 |
Why?
|
Cholesterol, LDL | 13 | 2009 | 2334 | 0.500 |
Why?
|
Microvessels | 1 | 2019 | 544 | 0.490 |
Why?
|
Licensure, Medical | 1 | 2014 | 63 | 0.480 |
Why?
|
Acetylcholine | 4 | 2014 | 622 | 0.470 |
Why?
|
Vascular Surgical Procedures | 4 | 2017 | 1471 | 0.460 |
Why?
|
Hypolipidemic Agents | 5 | 2002 | 606 | 0.450 |
Why?
|
Treatment Outcome | 33 | 2023 | 62693 | 0.450 |
Why?
|
Vitamin E | 6 | 2006 | 870 | 0.440 |
Why?
|
Specialty Boards | 1 | 2014 | 227 | 0.440 |
Why?
|
Myocardial Revascularization | 2 | 2011 | 841 | 0.430 |
Why?
|
Myocardial Ischemia | 8 | 2014 | 2146 | 0.430 |
Why?
|
Aortic Rupture | 1 | 2015 | 310 | 0.420 |
Why?
|
Amlodipine | 1 | 2012 | 79 | 0.410 |
Why?
|
Cardiovascular Agents | 2 | 2018 | 845 | 0.410 |
Why?
|
Drug Therapy, Combination | 8 | 2023 | 6478 | 0.410 |
Why?
|
Drug Administration Schedule | 5 | 2021 | 4935 | 0.400 |
Why?
|
Humans | 154 | 2023 | 739398 | 0.400 |
Why?
|
Coronary Sinus | 1 | 2012 | 87 | 0.400 |
Why?
|
Hemorrhage | 5 | 2023 | 3441 | 0.390 |
Why?
|
Serum Amyloid A Protein | 3 | 2013 | 121 | 0.390 |
Why?
|
Aspirin | 3 | 2023 | 3268 | 0.390 |
Why?
|
Risk Factors | 39 | 2023 | 71974 | 0.390 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2012 | 124 | 0.380 |
Why?
|
Ascorbic Acid | 6 | 2006 | 649 | 0.380 |
Why?
|
Septal Occluder Device | 1 | 2011 | 129 | 0.380 |
Why?
|
Blood Vessels | 1 | 2016 | 1126 | 0.370 |
Why?
|
Guidelines as Topic | 1 | 2017 | 1407 | 0.370 |
Why?
|
Coronary Thrombosis | 2 | 2020 | 494 | 0.360 |
Why?
|
Enalapril | 1 | 2012 | 323 | 0.360 |
Why?
|
Disease Management | 4 | 2017 | 2448 | 0.360 |
Why?
|
Mastitis | 2 | 2001 | 41 | 0.360 |
Why?
|
Gastrointestinal Tract | 1 | 2016 | 814 | 0.360 |
Why?
|
Cholesterol | 8 | 1999 | 2900 | 0.350 |
Why?
|
Foreign-Body Migration | 1 | 2011 | 222 | 0.350 |
Why?
|
Aorta, Thoracic | 2 | 2015 | 1078 | 0.350 |
Why?
|
Subclavian Steal Syndrome | 1 | 2009 | 23 | 0.350 |
Why?
|
Graft Occlusion, Vascular | 4 | 2020 | 551 | 0.340 |
Why?
|
Subclavian Artery | 1 | 2009 | 129 | 0.340 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2015 | 678 | 0.340 |
Why?
|
Peripheral Vascular Diseases | 1 | 2012 | 550 | 0.330 |
Why?
|
Foramen Ovale, Patent | 1 | 2011 | 222 | 0.330 |
Why?
|
Atrial Fibrillation | 4 | 2022 | 5003 | 0.330 |
Why?
|
Blood Flow Velocity | 5 | 2019 | 1437 | 0.320 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1129 | 0.320 |
Why?
|
Embolism | 1 | 2011 | 408 | 0.320 |
Why?
|
Limb Salvage | 3 | 2023 | 433 | 0.320 |
Why?
|
Propensity Score | 4 | 2016 | 1749 | 0.320 |
Why?
|
Vascular Diseases | 1 | 2016 | 1152 | 0.310 |
Why?
|
Endothelin-1 | 3 | 2009 | 313 | 0.300 |
Why?
|
Antioxidants | 6 | 2006 | 1659 | 0.300 |
Why?
|
Prosthesis Design | 4 | 2016 | 2110 | 0.300 |
Why?
|
Male | 85 | 2023 | 349022 | 0.290 |
Why?
|
Vasomotor System | 6 | 2005 | 210 | 0.290 |
Why?
|
Neovascularization, Physiologic | 1 | 2014 | 1352 | 0.280 |
Why?
|
Arteriovenous Shunt, Surgical | 1 | 2009 | 281 | 0.280 |
Why?
|
Antihypertensive Agents | 3 | 2012 | 2039 | 0.280 |
Why?
|
Proportional Hazards Models | 8 | 2016 | 12328 | 0.280 |
Why?
|
Endarterectomy, Carotid | 1 | 2011 | 543 | 0.270 |
Why?
|
Multivariate Analysis | 10 | 2016 | 12237 | 0.270 |
Why?
|
Arteries | 3 | 2018 | 1116 | 0.260 |
Why?
|
CD40 Ligand | 2 | 2004 | 527 | 0.260 |
Why?
|
Ambulatory Care Facilities | 1 | 2011 | 928 | 0.260 |
Why?
|
Time Factors | 20 | 2020 | 40050 | 0.260 |
Why?
|
Middle Aged | 67 | 2021 | 212863 | 0.260 |
Why?
|
Cause of Death | 1 | 2015 | 3564 | 0.250 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2017 | 9812 | 0.250 |
Why?
|
Ankle Brachial Index | 2 | 2018 | 154 | 0.250 |
Why?
|
Upper Extremity | 1 | 2009 | 642 | 0.250 |
Why?
|
Electrocardiography | 9 | 2013 | 6426 | 0.240 |
Why?
|
Advisory Committees | 3 | 2017 | 770 | 0.240 |
Why?
|
American Heart Association | 3 | 2017 | 1050 | 0.240 |
Why?
|
Carotid Stenosis | 1 | 2011 | 851 | 0.230 |
Why?
|
Vasoconstriction | 2 | 2009 | 601 | 0.230 |
Why?
|
Tissue Plasminogen Activator | 2 | 2013 | 1263 | 0.230 |
Why?
|
Coronary Circulation | 7 | 2009 | 1578 | 0.220 |
Why?
|
Fibrinolytic Agents | 2 | 2023 | 2149 | 0.220 |
Why?
|
Coronary Restenosis | 2 | 2003 | 423 | 0.220 |
Why?
|
Angioplasty, Balloon, Laser-Assisted | 1 | 2002 | 25 | 0.220 |
Why?
|
Lovastatin | 2 | 2002 | 120 | 0.220 |
Why?
|
Practice Guidelines as Topic | 4 | 2016 | 7274 | 0.220 |
Why?
|
Aged | 48 | 2023 | 162698 | 0.220 |
Why?
|
Nitric Oxide | 6 | 2001 | 2121 | 0.210 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1637 | 0.210 |
Why?
|
Female | 70 | 2021 | 378853 | 0.210 |
Why?
|
Postoperative Care | 2 | 2021 | 1477 | 0.210 |
Why?
|
Syndrome | 6 | 2003 | 3241 | 0.200 |
Why?
|
Breast Feeding | 2 | 2001 | 1334 | 0.200 |
Why?
|
Anticoagulants | 4 | 2023 | 4582 | 0.200 |
Why?
|
Constriction, Pathologic | 4 | 2018 | 1096 | 0.200 |
Why?
|
Boston | 3 | 2023 | 9314 | 0.200 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2015 | 2216 | 0.190 |
Why?
|
Biomedical Research | 2 | 2016 | 3301 | 0.190 |
Why?
|
Inflammation Mediators | 2 | 2013 | 1890 | 0.190 |
Why?
|
Clinical Competence | 3 | 2014 | 4671 | 0.190 |
Why?
|
Atherosclerosis | 4 | 2014 | 3401 | 0.190 |
Why?
|
Diet Surveys | 2 | 1997 | 1165 | 0.180 |
Why?
|
Renal Dialysis | 1 | 2009 | 1780 | 0.180 |
Why?
|
Saphenous Vein | 2 | 2020 | 527 | 0.180 |
Why?
|
Australia | 8 | 2013 | 1162 | 0.180 |
Why?
|
Ambulatory Care | 1 | 2011 | 2711 | 0.180 |
Why?
|
Lipoproteins, LDL | 6 | 2005 | 626 | 0.180 |
Why?
|
Brachial Artery | 5 | 2004 | 370 | 0.180 |
Why?
|
New South Wales | 6 | 2001 | 66 | 0.180 |
Why?
|
Laboratories | 3 | 2012 | 458 | 0.180 |
Why?
|
United States | 16 | 2021 | 69573 | 0.180 |
Why?
|
Fibrinogen | 2 | 1993 | 895 | 0.170 |
Why?
|
Endpoint Determination | 2 | 2013 | 598 | 0.170 |
Why?
|
Hospital Mortality | 3 | 2013 | 5305 | 0.170 |
Why?
|
Secondary Prevention | 3 | 2012 | 1516 | 0.170 |
Why?
|
Recurrence | 8 | 2013 | 8307 | 0.160 |
Why?
|
Hypercholesterolemia | 6 | 2003 | 1143 | 0.160 |
Why?
|
Emergency Treatment | 2 | 2012 | 516 | 0.160 |
Why?
|
Nitroglycerin | 5 | 2002 | 325 | 0.160 |
Why?
|
Stroke | 3 | 2012 | 9898 | 0.150 |
Why?
|
Risk Assessment | 9 | 2019 | 23294 | 0.150 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2023 | 525 | 0.150 |
Why?
|
Brain Ischemia | 1 | 2011 | 3246 | 0.150 |
Why?
|
Acute Disease | 6 | 2003 | 7128 | 0.150 |
Why?
|
Diabetes Mellitus | 1 | 2015 | 5702 | 0.150 |
Why?
|
Cardiac Surgical Procedures | 1 | 2011 | 3517 | 0.140 |
Why?
|
Quality of Life | 4 | 2022 | 12640 | 0.140 |
Why?
|
Logistic Models | 5 | 2016 | 13402 | 0.140 |
Why?
|
Dietary Fats | 2 | 1997 | 2013 | 0.140 |
Why?
|
Immunodiffusion | 2 | 1993 | 163 | 0.140 |
Why?
|
Veterans Disability Claims | 1 | 2015 | 15 | 0.140 |
Why?
|
Heart Transplantation | 6 | 2009 | 3109 | 0.140 |
Why?
|
Analysis of Variance | 3 | 2015 | 6370 | 0.140 |
Why?
|
Societies, Scientific | 1 | 2017 | 220 | 0.140 |
Why?
|
Puerperal Disorders | 1 | 1998 | 279 | 0.130 |
Why?
|
Dietary Fats, Unsaturated | 1 | 1997 | 226 | 0.130 |
Why?
|
Predictive Value of Tests | 10 | 2018 | 15036 | 0.130 |
Why?
|
Risk | 4 | 2009 | 9684 | 0.130 |
Why?
|
Cardiac Imaging Techniques | 1 | 2018 | 269 | 0.130 |
Why?
|
Lipoprotein(a) | 3 | 2009 | 424 | 0.130 |
Why?
|
Follow-Up Studies | 12 | 2021 | 38942 | 0.130 |
Why?
|
Cardiovascular Diseases | 3 | 2012 | 15070 | 0.130 |
Why?
|
Retreatment | 2 | 2011 | 603 | 0.130 |
Why?
|
Double-Blind Method | 9 | 2020 | 11985 | 0.130 |
Why?
|
Nitrates | 1 | 1996 | 265 | 0.130 |
Why?
|
Writing | 1 | 2017 | 205 | 0.130 |
Why?
|
Registries | 6 | 2019 | 8039 | 0.130 |
Why?
|
Societies, Medical | 2 | 2017 | 3739 | 0.120 |
Why?
|
Magnesium Sulfate | 1 | 1995 | 68 | 0.120 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2018 | 280 | 0.120 |
Why?
|
Hospitals, Veterans | 1 | 2016 | 404 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 20055 | 0.120 |
Why?
|
Electrocardiography, Ambulatory | 2 | 2000 | 584 | 0.120 |
Why?
|
Retrospective Studies | 11 | 2023 | 76631 | 0.120 |
Why?
|
Adult | 40 | 2019 | 213394 | 0.120 |
Why?
|
Digoxin | 1 | 1995 | 251 | 0.120 |
Why?
|
Severity of Illness Index | 4 | 2018 | 15511 | 0.120 |
Why?
|
Odds Ratio | 7 | 2013 | 9846 | 0.120 |
Why?
|
Inflammation | 6 | 2009 | 10534 | 0.120 |
Why?
|
Mitral Valve Insufficiency | 1 | 2023 | 1408 | 0.120 |
Why?
|
Salicylates | 1 | 2014 | 126 | 0.120 |
Why?
|
Cost-Benefit Analysis | 5 | 2019 | 5462 | 0.110 |
Why?
|
Calcinosis | 1 | 2001 | 1493 | 0.110 |
Why?
|
Regional Blood Flow | 5 | 2009 | 1528 | 0.110 |
Why?
|
Neopterin | 1 | 2012 | 56 | 0.110 |
Why?
|
Apolipoproteins B | 2 | 2009 | 373 | 0.100 |
Why?
|
Edetic Acid | 1 | 1992 | 277 | 0.100 |
Why?
|
Reproducibility of Results | 9 | 2019 | 19811 | 0.100 |
Why?
|
Hemodynamics | 6 | 2012 | 4197 | 0.100 |
Why?
|
Long-Term Care | 1 | 2015 | 606 | 0.100 |
Why?
|
Thrombosis | 4 | 2012 | 2961 | 0.100 |
Why?
|
Exercise | 2 | 2018 | 5591 | 0.100 |
Why?
|
Epoprostenol | 1 | 2012 | 252 | 0.100 |
Why?
|
Atherectomy, Coronary | 2 | 2001 | 148 | 0.100 |
Why?
|
Receptors, Interleukin-1 | 1 | 2012 | 261 | 0.100 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2012 | 153 | 0.100 |
Why?
|
Apolipoproteins A | 1 | 1991 | 92 | 0.100 |
Why?
|
Databases, Factual | 2 | 2016 | 7690 | 0.100 |
Why?
|
Interleukin-18 | 1 | 2012 | 248 | 0.090 |
Why?
|
Pulmonary Veno-Occlusive Disease | 1 | 2010 | 66 | 0.090 |
Why?
|
Hospitals, Teaching | 2 | 1996 | 1166 | 0.090 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2011 | 205 | 0.090 |
Why?
|
Hypertrophy, Left Ventricular | 2 | 2012 | 851 | 0.090 |
Why?
|
Drug Therapy | 1 | 2013 | 497 | 0.090 |
Why?
|
Family Practice | 4 | 1998 | 516 | 0.090 |
Why?
|
Device Removal | 2 | 2011 | 648 | 0.090 |
Why?
|
Receptor, Endothelin A | 3 | 2009 | 58 | 0.090 |
Why?
|
Quality Indicators, Health Care | 3 | 2014 | 1828 | 0.090 |
Why?
|
Heart Failure | 2 | 2023 | 10793 | 0.090 |
Why?
|
Utilization Review | 1 | 1991 | 392 | 0.090 |
Why?
|
Energy Intake | 1 | 1997 | 2135 | 0.090 |
Why?
|
Heart Arrest | 2 | 2013 | 1458 | 0.080 |
Why?
|
Angiography | 2 | 2019 | 1634 | 0.080 |
Why?
|
Quality Assurance, Health Care | 3 | 2014 | 2213 | 0.080 |
Why?
|
Pulmonary Artery | 2 | 2012 | 1909 | 0.080 |
Why?
|
Asymptomatic Diseases | 1 | 2011 | 549 | 0.080 |
Why?
|
Aged, 80 and over | 13 | 2015 | 57650 | 0.080 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2012 | 637 | 0.080 |
Why?
|
Vasodilator Agents | 4 | 2014 | 976 | 0.080 |
Why?
|
History, 21st Century | 1 | 2014 | 1534 | 0.080 |
Why?
|
Interleukin-6 | 3 | 2013 | 3194 | 0.080 |
Why?
|
Incidental Findings | 1 | 2013 | 690 | 0.080 |
Why?
|
Catheters | 1 | 2011 | 419 | 0.080 |
Why?
|
Cholesterol, HDL | 4 | 2003 | 1807 | 0.080 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3510 | 0.080 |
Why?
|
Blood Pressure | 4 | 2003 | 8554 | 0.080 |
Why?
|
Disease Progression | 8 | 2013 | 13237 | 0.080 |
Why?
|
Educational Measurement | 1 | 2014 | 1205 | 0.080 |
Why?
|
Stress, Mechanical | 5 | 2007 | 1682 | 0.080 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2184 | 0.080 |
Why?
|
Iliac Artery | 2 | 2007 | 363 | 0.080 |
Why?
|
Cohort Studies | 6 | 2015 | 40389 | 0.070 |
Why?
|
Host-Pathogen Interactions | 1 | 2016 | 1476 | 0.070 |
Why?
|
Endocarditis, Bacterial | 1 | 2011 | 453 | 0.070 |
Why?
|
Prosthesis Implantation | 1 | 2012 | 640 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2952 | 0.070 |
Why?
|
Epidemiologic Methods | 1 | 1992 | 1364 | 0.070 |
Why?
|
Peptides, Cyclic | 3 | 2009 | 400 | 0.070 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2009 | 425 | 0.070 |
Why?
|
Physical Therapy Modalities | 1 | 1991 | 545 | 0.070 |
Why?
|
Early Diagnosis | 1 | 2011 | 1186 | 0.070 |
Why?
|
Heart Conduction System | 1 | 2012 | 1049 | 0.070 |
Why?
|
Blood Chemical Analysis | 1 | 1988 | 441 | 0.070 |
Why?
|
Triglycerides | 4 | 2003 | 2447 | 0.070 |
Why?
|
Tachycardia, Ventricular | 1 | 1995 | 1271 | 0.070 |
Why?
|
Azetidines | 1 | 2007 | 142 | 0.070 |
Why?
|
Arrhythmias, Cardiac | 1 | 1996 | 2265 | 0.070 |
Why?
|
Phospholipids | 1 | 2009 | 783 | 0.070 |
Why?
|
Prosthesis-Related Infections | 1 | 2011 | 538 | 0.070 |
Why?
|
Postoperative Complications | 2 | 2010 | 15194 | 0.060 |
Why?
|
Respiratory Tract Diseases | 1 | 1991 | 718 | 0.060 |
Why?
|
Preventive Medicine | 1 | 1987 | 263 | 0.060 |
Why?
|
Patient Selection | 3 | 2012 | 4211 | 0.060 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2010 | 591 | 0.060 |
Why?
|
Mass Screening | 3 | 1990 | 5265 | 0.060 |
Why?
|
Anaphylaxis | 1 | 2012 | 747 | 0.060 |
Why?
|
Pulmonary Veins | 1 | 2010 | 759 | 0.060 |
Why?
|
Exercise Test | 3 | 2018 | 2069 | 0.060 |
Why?
|
Lipid Metabolism | 2 | 2005 | 1891 | 0.060 |
Why?
|
Evidence-Based Medicine | 3 | 2016 | 3606 | 0.060 |
Why?
|
Sensitivity and Specificity | 5 | 2018 | 14740 | 0.060 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 2277 | 0.060 |
Why?
|
Oxidative Stress | 3 | 2006 | 3087 | 0.060 |
Why?
|
Gadolinium DTPA | 1 | 2007 | 836 | 0.060 |
Why?
|
Incidence | 5 | 2013 | 20913 | 0.060 |
Why?
|
Professional Review Organizations | 2 | 2012 | 50 | 0.050 |
Why?
|
Treatment Failure | 1 | 2008 | 2614 | 0.050 |
Why?
|
Solubility | 1 | 2004 | 1083 | 0.050 |
Why?
|
Survival Rate | 2 | 2015 | 12761 | 0.050 |
Why?
|
Echocardiography | 2 | 2011 | 5098 | 0.050 |
Why?
|
omega-N-Methylarginine | 1 | 2001 | 111 | 0.050 |
Why?
|
Compliance | 1 | 2001 | 105 | 0.050 |
Why?
|
Defibrillators, Implantable | 1 | 2011 | 1441 | 0.050 |
Why?
|
Animals | 9 | 2022 | 168368 | 0.050 |
Why?
|
Prognosis | 4 | 2019 | 28901 | 0.050 |
Why?
|
Nitric Oxide Donors | 1 | 2001 | 121 | 0.050 |
Why?
|
Reactive Oxygen Species | 1 | 2009 | 2084 | 0.050 |
Why?
|
Anatomy, Cross-Sectional | 1 | 2001 | 141 | 0.050 |
Why?
|
Cell Adhesion Molecules | 2 | 1998 | 1599 | 0.050 |
Why?
|
Apolipoproteins | 1 | 2003 | 315 | 0.050 |
Why?
|
Hypertension, Pulmonary | 1 | 2012 | 1525 | 0.050 |
Why?
|
Contrast Media | 2 | 2012 | 5293 | 0.050 |
Why?
|
Cardiovascular Surgical Procedures | 2 | 2012 | 194 | 0.050 |
Why?
|
Regression Analysis | 1 | 2011 | 6452 | 0.050 |
Why?
|
Total Quality Management | 2 | 2012 | 274 | 0.050 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2011 | 2044 | 0.050 |
Why?
|
Insulin | 1 | 2015 | 6569 | 0.050 |
Why?
|
Prospective Studies | 6 | 2023 | 53037 | 0.050 |
Why?
|
Heart Diseases | 2 | 1990 | 2782 | 0.040 |
Why?
|
ROC Curve | 1 | 2007 | 3526 | 0.040 |
Why?
|
Elasticity | 1 | 2001 | 656 | 0.040 |
Why?
|
Kidney | 1 | 2015 | 7144 | 0.040 |
Why?
|
Troponin | 1 | 2003 | 516 | 0.040 |
Why?
|
Cross-Over Studies | 2 | 2014 | 2030 | 0.040 |
Why?
|
Heart Ventricles | 1 | 2011 | 3799 | 0.040 |
Why?
|
Terrorism | 1 | 2002 | 211 | 0.040 |
Why?
|
Developing Countries | 2 | 2003 | 2779 | 0.040 |
Why?
|
Autoantibodies | 2 | 2009 | 2020 | 0.040 |
Why?
|
Inguinal Canal | 1 | 2019 | 69 | 0.040 |
Why?
|
Chlamydophila pneumoniae | 1 | 1998 | 55 | 0.040 |
Why?
|
Linear Models | 4 | 2013 | 5948 | 0.040 |
Why?
|
Hypertension | 2 | 2012 | 8431 | 0.040 |
Why?
|
Evaluation Studies as Topic | 2 | 1991 | 1676 | 0.040 |
Why?
|
Radiography | 1 | 2009 | 6998 | 0.040 |
Why?
|
Health Behavior | 1 | 1990 | 2624 | 0.040 |
Why?
|
Nitric Oxide Synthase | 1 | 2001 | 916 | 0.040 |
Why?
|
Platelet Activation | 1 | 2002 | 672 | 0.040 |
Why?
|
Education, Medical, Undergraduate | 1 | 1987 | 999 | 0.040 |
Why?
|
Massachusetts | 1 | 2011 | 8669 | 0.040 |
Why?
|
Coronary Vessel Anomalies | 1 | 2001 | 312 | 0.040 |
Why?
|
Vasoconstrictor Agents | 1 | 2001 | 642 | 0.040 |
Why?
|
Consensus | 2 | 2017 | 2913 | 0.040 |
Why?
|
Unnecessary Procedures | 1 | 2001 | 428 | 0.040 |
Why?
|
Medicare | 1 | 2015 | 6497 | 0.040 |
Why?
|
Chronic Disease | 2 | 2022 | 9133 | 0.040 |
Why?
|
Wettability | 1 | 1996 | 23 | 0.040 |
Why?
|
Ultrasonography | 4 | 2005 | 5941 | 0.040 |
Why?
|
Administration, Sublingual | 1 | 1996 | 56 | 0.040 |
Why?
|
Catheter Ablation | 1 | 2010 | 2737 | 0.040 |
Why?
|
Absorption | 1 | 1996 | 248 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8605 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 1990 | 3021 | 0.040 |
Why?
|
Cost Allocation | 1 | 1996 | 51 | 0.030 |
Why?
|
Emergency Service, Hospital | 2 | 2012 | 7626 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2005 | 10945 | 0.030 |
Why?
|
Ankle | 1 | 2019 | 319 | 0.030 |
Why?
|
Thrombectomy | 1 | 2001 | 673 | 0.030 |
Why?
|
Infusions, Intravenous | 2 | 2012 | 2270 | 0.030 |
Why?
|
Diabetic Angiopathies | 1 | 2001 | 821 | 0.030 |
Why?
|
Benchmarking | 2 | 2012 | 1034 | 0.030 |
Why?
|
Stroke Volume | 2 | 2022 | 4941 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2013 | 705 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 7897 | 0.030 |
Why?
|
Chlamydia Infections | 1 | 1998 | 364 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2012 | 5128 | 0.030 |
Why?
|
Physician's Role | 1 | 2002 | 943 | 0.030 |
Why?
|
Cholestyramine Resin | 1 | 1994 | 24 | 0.030 |
Why?
|
Hospitals, Public | 1 | 1996 | 204 | 0.030 |
Why?
|
Echocardiography, Transesophageal | 2 | 2011 | 1128 | 0.030 |
Why?
|
Death, Sudden, Cardiac | 1 | 2022 | 1542 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 1998 | 719 | 0.030 |
Why?
|
Diabetes Complications | 1 | 2001 | 1356 | 0.030 |
Why?
|
Rest | 1 | 2018 | 904 | 0.030 |
Why?
|
Brachytherapy | 1 | 2001 | 1247 | 0.030 |
Why?
|
Health Services | 1 | 1998 | 757 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2013 | 6871 | 0.030 |
Why?
|
San Francisco | 1 | 2012 | 159 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 1995 | 1421 | 0.030 |
Why?
|
False Negative Reactions | 1 | 1993 | 589 | 0.030 |
Why?
|
Cytomegalovirus Infections | 1 | 1998 | 808 | 0.030 |
Why?
|
Neutropenia | 1 | 1997 | 888 | 0.030 |
Why?
|
Ambulances | 1 | 2012 | 95 | 0.030 |
Why?
|
Exercise Therapy | 1 | 2019 | 897 | 0.030 |
Why?
|
Lipids | 3 | 2005 | 3307 | 0.030 |
Why?
|
Observer Variation | 2 | 2013 | 2589 | 0.030 |
Why?
|
Drainage, Postural | 1 | 1991 | 1 | 0.020 |
Why?
|
Urban Health Services | 1 | 2012 | 179 | 0.020 |
Why?
|
Percussion | 1 | 1991 | 18 | 0.020 |
Why?
|
Haemophilus influenzae | 1 | 2011 | 171 | 0.020 |
Why?
|
Medication Therapy Management | 1 | 2012 | 126 | 0.020 |
Why?
|
Patient Care Team | 2 | 2012 | 2527 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2001 | 3802 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2001 | 4332 | 0.020 |
Why?
|
Suction | 1 | 2011 | 267 | 0.020 |
Why?
|
Water | 1 | 1996 | 1377 | 0.020 |
Why?
|
Heart Rate | 2 | 2003 | 4095 | 0.020 |
Why?
|
Fever | 1 | 1997 | 1607 | 0.020 |
Why?
|
Education, Medical, Graduate | 2 | 2012 | 2275 | 0.020 |
Why?
|
Patient Admission | 1 | 1997 | 1383 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2012 | 982 | 0.020 |
Why?
|
Sampling Studies | 1 | 1991 | 624 | 0.020 |
Why?
|
North America | 1 | 2013 | 1249 | 0.020 |
Why?
|
Hemoptysis | 1 | 2010 | 155 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2007 | 35326 | 0.020 |
Why?
|
Anti-Bacterial Agents | 3 | 2011 | 7136 | 0.020 |
Why?
|
Community Health Nursing | 1 | 1988 | 24 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2003 | 3844 | 0.020 |
Why?
|
Sputum | 1 | 1991 | 474 | 0.020 |
Why?
|
Peptides | 1 | 2001 | 4395 | 0.020 |
Why?
|
Reagent Strips | 1 | 1988 | 39 | 0.020 |
Why?
|
Photometry | 1 | 1988 | 58 | 0.020 |
Why?
|
Pneumonia | 1 | 2000 | 2102 | 0.020 |
Why?
|
Medical History Taking | 1 | 2012 | 782 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 1994 | 1675 | 0.020 |
Why?
|
Smoking | 3 | 2003 | 8960 | 0.020 |
Why?
|
Patient Compliance | 1 | 1998 | 2679 | 0.020 |
Why?
|
Troponin I | 1 | 2012 | 616 | 0.020 |
Why?
|
Case-Control Studies | 3 | 2009 | 21694 | 0.020 |
Why?
|
South Africa | 1 | 2013 | 1743 | 0.020 |
Why?
|
Cross-Sectional Studies | 3 | 2013 | 24714 | 0.020 |
Why?
|
Emergencies | 1 | 2013 | 1152 | 0.020 |
Why?
|
Hemorheology | 1 | 2007 | 145 | 0.020 |
Why?
|
Drug Resistance | 1 | 2012 | 1610 | 0.020 |
Why?
|
Emergency Medical Services | 2 | 2012 | 1904 | 0.020 |
Why?
|
Europe | 1 | 2013 | 3331 | 0.020 |
Why?
|
Cost of Illness | 1 | 1996 | 1849 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2012 | 1453 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 2974 | 0.020 |
Why?
|
Elastic Tissue | 1 | 2005 | 65 | 0.020 |
Why?
|
Heart Atria | 1 | 2011 | 1342 | 0.020 |
Why?
|
Health Care Costs | 1 | 2019 | 3226 | 0.020 |
Why?
|
Insulin Resistance | 2 | 2014 | 3858 | 0.020 |
Why?
|
Catheterization | 1 | 2010 | 1466 | 0.020 |
Why?
|
Primary Prevention | 1 | 1992 | 1165 | 0.020 |
Why?
|
Microcirculation | 1 | 2009 | 1285 | 0.020 |
Why?
|
Immunoglobulin G | 2 | 2009 | 4522 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 2009 | 1537 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2012 | 1735 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2001 | 8977 | 0.010 |
Why?
|
Diet Therapy | 1 | 2005 | 154 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 2009 | 2184 | 0.010 |
Why?
|
Health Education | 1 | 1990 | 1054 | 0.010 |
Why?
|
Blood Viscosity | 1 | 2003 | 124 | 0.010 |
Why?
|
Egypt | 1 | 2003 | 100 | 0.010 |
Why?
|
Equipment Design | 1 | 2011 | 3583 | 0.010 |
Why?
|
Adolescent | 4 | 2002 | 85405 | 0.010 |
Why?
|
Hospitalization | 2 | 2012 | 10208 | 0.010 |
Why?
|
Thromboembolism | 1 | 2009 | 984 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6516 | 0.010 |
Why?
|
Dyspnea | 1 | 2010 | 1295 | 0.010 |
Why?
|
Thailand | 1 | 2003 | 296 | 0.010 |
Why?
|
Philosophy, Medical | 1 | 2002 | 80 | 0.010 |
Why?
|
Sex Factors | 2 | 1997 | 10398 | 0.010 |
Why?
|
Beta Particles | 1 | 2001 | 50 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 1997 | 13880 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 2 | 2005 | 4035 | 0.010 |
Why?
|
Reference Values | 1 | 1988 | 4983 | 0.010 |
Why?
|
Phagocytes | 1 | 2002 | 297 | 0.010 |
Why?
|
Forearm | 1 | 2003 | 407 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2002 | 637 | 0.010 |
Why?
|
Platelet Function Tests | 1 | 2002 | 270 | 0.010 |
Why?
|
Kenya | 1 | 2003 | 678 | 0.010 |
Why?
|
Schools, Medical | 1 | 1987 | 878 | 0.010 |
Why?
|
Infant, Low Birth Weight | 1 | 1984 | 848 | 0.010 |
Why?
|
Simvastatin | 1 | 2002 | 360 | 0.010 |
Why?
|
Biological Availability | 1 | 2000 | 390 | 0.010 |
Why?
|
Tunica Intima | 1 | 2002 | 464 | 0.010 |
Why?
|
Infant Mortality | 1 | 1984 | 749 | 0.010 |
Why?
|
Child | 3 | 2012 | 77033 | 0.010 |
Why?
|
Teaching | 1 | 1987 | 1166 | 0.010 |
Why?
|
Bibliometrics | 1 | 2003 | 340 | 0.010 |
Why?
|
Age Factors | 2 | 1997 | 18349 | 0.010 |
Why?
|
Feeding Behavior | 1 | 1991 | 3180 | 0.010 |
Why?
|
Living Donors | 1 | 2002 | 617 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 1991 | 3945 | 0.010 |
Why?
|
Length of Stay | 2 | 1997 | 6295 | 0.010 |
Why?
|
Hirudins | 1 | 1999 | 182 | 0.010 |
Why?
|
Referral and Consultation | 1 | 1991 | 3514 | 0.010 |
Why?
|
Publications | 1 | 2000 | 194 | 0.010 |
Why?
|
Hyperinsulinism | 1 | 2001 | 415 | 0.010 |
Why?
|
Perfusion | 1 | 2002 | 1354 | 0.010 |
Why?
|
Oncology Service, Hospital | 1 | 1997 | 57 | 0.010 |
Why?
|
Seroepidemiologic Studies | 1 | 1998 | 401 | 0.010 |
Why?
|
China | 1 | 2003 | 2225 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12948 | 0.010 |
Why?
|
Blood Coagulation | 1 | 2002 | 1122 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2000 | 1580 | 0.010 |
Why?
|
India | 1 | 2003 | 2189 | 0.010 |
Why?
|
Telemedicine | 1 | 2013 | 2844 | 0.010 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2002 | 1504 | 0.010 |
Why?
|
Hyperlipidemias | 1 | 2001 | 785 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2012 | 4239 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2002 | 1820 | 0.010 |
Why?
|
Macrophages | 2 | 2002 | 5631 | 0.010 |
Why?
|
Publishing | 1 | 2003 | 828 | 0.010 |
Why?
|
Creatine Kinase | 1 | 1997 | 694 | 0.010 |
Why?
|
International Cooperation | 1 | 2002 | 1420 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 15153 | 0.010 |
Why?
|
Physicians | 1 | 2013 | 4539 | 0.010 |
Why?
|
Postoperative Period | 1 | 2000 | 1835 | 0.010 |
Why?
|
Students, Medical | 1 | 1987 | 1850 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 1510 | 0.010 |
Why?
|
Curriculum | 1 | 1987 | 3575 | 0.010 |
Why?
|
Rabbits | 1 | 2000 | 4882 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1997 | 1581 | 0.010 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2003 | 1381 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2003 | 5058 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2006 | 4143 | 0.010 |
Why?
|
Protein Kinase C | 1 | 1997 | 1223 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2000 | 2448 | 0.010 |
Why?
|
Isoenzymes | 1 | 1997 | 1720 | 0.010 |
Why?
|
Cell Division | 1 | 2000 | 4575 | 0.010 |
Why?
|
Hyperglycemia | 1 | 2001 | 1357 | 0.010 |
Why?
|
Diet | 1 | 1990 | 7876 | 0.010 |
Why?
|
Periodicals as Topic | 1 | 2003 | 1428 | 0.010 |
Why?
|
Heparin | 1 | 1999 | 1637 | 0.010 |
Why?
|
Blood Platelets | 1 | 2002 | 2506 | 0.010 |
Why?
|
Thrombolytic Therapy | 1 | 2000 | 2155 | 0.010 |
Why?
|
Cross Infection | 1 | 2000 | 1414 | 0.010 |
Why?
|
Pyridines | 1 | 2002 | 2810 | 0.010 |
Why?
|
Bacteremia | 1 | 1997 | 957 | 0.010 |
Why?
|
Pilot Projects | 1 | 2003 | 8275 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1999 | 6610 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2001 | 2861 | 0.010 |
Why?
|
Obesity | 1 | 1991 | 12643 | 0.010 |
Why?
|
Neoplasms | 1 | 1997 | 21507 | 0.010 |
Why?
|
Cytokines | 1 | 2002 | 7298 | 0.000 |
Why?
|
RNA, Messenger | 1 | 2002 | 13002 | 0.000 |
Why?
|
Stress, Psychological | 1 | 2002 | 4212 | 0.000 |
Why?
|
Cells, Cultured | 1 | 2002 | 19220 | 0.000 |
Why?
|
Peptide Fragments | 1 | 1999 | 5076 | 0.000 |
Why?
|
Central Nervous System Diseases | 1 | 1984 | 522 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 1997 | 10142 | 0.000 |
Why?
|
Developmental Disabilities | 1 | 1984 | 1445 | 0.000 |
Why?
|
Mice | 1 | 2002 | 81002 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 1997 | 13635 | 0.000 |
Why?
|
Health Status | 1 | 1984 | 4013 | 0.000 |
Why?
|
Socioeconomic Factors | 1 | 1984 | 7726 | 0.000 |
Why?
|
Patient Readmission | 1 | 1984 | 3106 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1984 | 25470 | 0.000 |
Why?
|